Vietnam Gram Negative Infection Therapeutics Market Report 2023 to 2030

Vietnam Gram-Negative Infection Therapeutics Market Analysis

$ 3999

The Vietnam Gram-Negative Infection Therapeutics Market was valued at $74.4 Mn in 2023 and is predicted to grow at a CAGR of 6.13% from 2023 to 2030 to $112.8 Mn by 2030. This growth is fuelled by factors such as the increasing prevalence of antibiotic resistance, elevated rates of colonization with resistant strains, and rising mortality rates. Key players in this market include Merck, Takeda, Novartis, and other notable companies.

ID: IN10VNPH563 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Aryan Patel

Buy Now

Vietnam Gram-Negative Infection Therapeutics Market Executive Summary

The Vietnam Gram-Negative Infection Therapeutics Market was valued at $74.4 Mn in 2023 and is predicted to grow at a CAGR of 6.13% from 2023 to 2030 to $112.8 Mn by 2030.

Gram-negative bacterial infections present a global health challenge due to increasing antimicrobial resistance (AMR), affecting diverse bacteria like Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Found in various healthcare settings, they lead to multiple illnesses like UTIs, bloodstream infections, and pneumonia. Rising AMR rates, including ESBL production and carbapenem resistance, highlight the urgent need for interventions. Challenges include limited diagnostic access and inappropriate antibiotic prescribing. Addressing this requires collaborative efforts involving healthcare sectors and policymakers, including enhanced surveillance, antimicrobial stewardship, and infection control measures.

The disease burden in Vietnam is significant, with a high prevalence of gram-negative infections. In 2020, approximately one-third of infections were attributed to gram-negative bacteria exhibiting concerning resistance to broad-spectrum antibiotics. Market growth is increased by the rising prevalence of antibiotic resistance, high rates of colonization with resistant strains, and increasing mortality rates. However, restricted healthcare accessibility, resource limitations, and regulatory framework ambiguity restrain the market.

Vietnam Gram Negative Infection Therapeutic Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Antibiotic Resistance: 35.6% of isolates were gram-negative bacteria in 2020. It is estimated that approximately one-third of infections were attributed to gram-negative bacteria exhibiting concerning resistance to broad-spectrum antibiotics. In 2020, 84.2% of Escherichia coli (E. coli) isolates showed resistance to at least one antibiotic, with 64.1% displaying resistance to three or more antibiotics. For Klebsiella pneumoniae isolates, 71.4% demonstrated resistance to at least one antibiotic, while 51.4% resisted three or more antibiotics.

Elevated Incidence of Resistant Strains Colonization: Numerous Vietnamese hospitals report heightened colonization rates of carbapenem-resistant Enterobacteriaceae (CRE) in neonatal and pediatric intensive care units, with central hospitals observing a significant rate of CRE colonization upon admission, indicating preexisting colonization in many patients.

Escalating Mortality Rates: Mortality rates correlate with CRE's resistance mechanisms, virulence factors, and susceptibility patterns. Colistin-resistant CRE strains exhibit higher crude mortality rates than carbapenem-resistant strains, underscoring the severity of the situation.

Market Restraints

Restricted Healthcare Accessibility: Scarce access to healthcare services in various regions leads to delays in diagnosing and treating gram-negative infections, impeding market growth.

Resource Limitations: Insufficient medical infrastructure and a shortage of skilled personnel hamper the healthcare system's capacity to manage gram-negative infections effectively and address antimicrobial resistance.

Regulatory Framework Ambiguity: The absence of a defined regulatory framework introduces uncertainty and impedes pharmaceutical companies and healthcare providers in developing and executing effective strategies to tackle these pressing healthcare challenges.

Regulatory Landscape and Reimbursement Scenario

In Vietnam, reimbursement for gram-negative infections is complex and influenced by factors like financial and healthcare burdens of antimicrobial resistance (AMR). The Vietnamese Social Security (VSS) health insurance program emphasizes affordability, requiring companies to prove their drugs' value through improved patient outcomes and cost-effectiveness analyses. Negotiations with the Ministry of Health (MOH) for pricing are made daily for inclusion on the reimbursement list, prioritizing highly effective drugs targeting critical MDR infections. The Drug Administration of Vietnam (DAV) oversees drug approval and import permits, referencing international regulatory authorities like WHO, EMA, and FDA for compliance and registration facilitation.

Competitive Landscape

Key Players

Here are some of the major key players in the Vietnam Gram-Negative Infection Therapeutics Market:

Merck & Co., Inc.
AstraZeneca
Roche
GlaxoSmithKline plc (GSK)
Pfizer Inc.
Sanofi-Aventis
Takeda Pharmaceutical Company Limited
Nektar Therapeutics
Baxter
Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Gram-Negative Infection Therapeutics Market Segmentation

By Drug Types

Antibiotics
Combination Therapies
Adjunctive Therapies

By Infection Types

Urinary Tract Infections (UTIs)
Pneumonia
Bloodstream Infections (Bacteraemia)
Wound/Surgical Site Infections
Gastrointestinal Infections
Meningitis
Hospital-Acquired Infections (HAIs)
Respiratory Tract Infections (RTIs)
Other Infections

By Route of Administration

Oral
Parenteral (injections, intravenous)
Topical

By Distribution Channel

Hospitals
Clinics
Ambulatory Surgical Centres
Home Healthcare
Long-term Care Facilities
Community Health Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.